Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
- Wednesday, March 10, 2021, 7:03
- Finance
- Add a comment
INDIANAPOLIS, March 10, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together significantly…
About the Author
adminasapcorp has written 41555 stories on this site.